Our History



  • Strategic Plan which sets out a clear programme of work until 2019 on NASH, oncology and neurodegenerative disease assays
  • Successful fundraising which enabled the launch of new assay projects
  • First scientific publication in PLOS ONE
  • Participation at the 2017 BIO International Convention


  • Member of delegation of 40 head of French companies visiting Japan, as part of the Eurobiomed and “Région PACA” initiative
  • Established scientific collaboration with the Gustave Roussy Institute
  • SAR assay development >> about SAR assay <<


  • Constitution of a strong Scientific Advisory Board. >> about scientific advisory board <<
  • COPD assay development (collaboration with Inserm). >> about COPD assay <<
  • American Thoracic Society abstract with Boehringer Ingelheim (May 2015, Denver, about our Idiopathic Pulmonary Fibrosis assay (IPF)).



  • Olivier JULE joins Biocellvia as CEO to support the growth of the company with his commercial and financial skills.
  • Establishment of the new strategy, based on dedicated assays.


  • Yvon JULE, researcher and scientist with more than 30 years of experience, creates Biocellvia, a start up specialized in compound validation assays.